Literature DB >> 11160781

Evolving treatment strategies for inflammatory bowel disease.

S B Hanauer1, T Dassopoulos.   

Abstract

Crohn's disease and ulcerative colitis are idiopathic inflammatory bowel diseases characterized by dysregulated intestinal immune responses in genetically susceptible hosts. Conventional approaches to the medical therapy of ulcerative colitis and Crohn's disease can now be directed at either induction or maintenance of remission to improve therapeutic efficacy while minimizing complications. Newer approaches have expanded the utility of conventional therapies by improving both safety and efficacy and highlight the importance of specific targets along the immunoinflammatory pathways. The combination of conventional and novel approaches now offers the potential of modifying the natural history of these diseases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11160781     DOI: 10.1146/annurev.med.52.1.299

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  8 in total

1.  The specific JNK inhibitor SP600125 targets tumour necrosis factor-alpha production and epithelial cell apoptosis in acute murine colitis.

Authors:  Kiran Assi; Rex Pillai; Antonio Gómez-Muñoz; David Owen; Baljinder Salh
Journal:  Immunology       Date:  2006-05       Impact factor: 7.397

2.  P-selectin glycoprotein ligand-1 is needed for sequential recruitment of T-helper 1 (Th1) and local generation of Th17 T cells in dextran sodium sulfate (DSS) colitis.

Authors:  Jeffrey B Brown; Paul Cheresh; Zheng Zhang; Hyunji Ryu; Elizabeth Managlia; Terrence A Barrett
Journal:  Inflamm Bowel Dis       Date:  2012-02       Impact factor: 5.325

3.  Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery.

Authors:  J Cosnes; I Nion-Larmurier; L Beaugerie; P Afchain; E Tiret; J-P Gendre
Journal:  Gut       Date:  2005-02       Impact factor: 23.059

4.  Benefit of theophylline administration in tacrolimus-induced nephrotoxicity in rats.

Authors:  Gwenn E McLaughlin; Michelle Schober; Maria Perez; Phillip Ruiz; Bernard W Steele; Carolyn Abitbol
Journal:  Pediatr Nephrol       Date:  2003-06-26       Impact factor: 3.714

5.  Short- and long-term efficacy of endoscopic balloon dilation in Crohn's disease strictures.

Authors:  Nicola de'Angelis; Maria Clotilde Carra; Osvaldo Borrelli; Barbara Bizzarri; Francesca Vincenzi; Fabiola Fornaroli; Giuseppina De Caro; Gian Luigi de'Angelis
Journal:  World J Gastroenterol       Date:  2013-05-07       Impact factor: 5.742

Review 6.  Gene therapy in the treatment of intestinal inflammation.

Authors:  Catherine van Montfrans; Anje A te Velde; Sander J H van Deventer; Maria Sol Rodriguez Pena
Journal:  Int J Colorectal Dis       Date:  2003-06-25       Impact factor: 2.571

7.  Budesonide ameliorates early portal hypertension in the rat: possible antiexudative splanchnic action.

Authors:  M Vega De Céniga; F Valdés; M A Aller; M P Nava; T Chivato; J Arias
Journal:  Inflammopharmacology       Date:  2003       Impact factor: 4.473

8.  MicroRNA profiling of tacrolimus-stimulated Jurkat human T lympocytes.

Authors:  Ho Kyun Lee; Sang Young Chung; Soo Jin Na Choi
Journal:  J Korean Surg Soc       Date:  2013-09-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.